IP Library Patent Application 13291526
Patent Application
App. No. 13/291,526

Methods and Compositions for the Treatment of Gastrointestinal Disorders

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/291,526
Abstract

Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase C (GC-C) receptor.

Claims (11)

1 - 52 . (canceled)

53 . A method for treating a patient suffering from a gastrointestinal disorder selected from the group consisting of gastroparesis and dyspepsia; the method comprising orally administering to the patient a composition comprising a polypeptide comprising the amino acid sequence Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu (SEQ ID NO: 73) or Asn Asp Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu (SEQ ID NO: 44), wherein the polypeptide activates the guanylate cyclase C receptor, thereby treating the disorder.

54 . The method of claim 53 , wherein the gastrointestinal disorder is gastroparesis.

55 . The method of claim 53 , wherein the gastrointestinal disorder is dyspepsia.

56 . The method of claim 55 , wherein the dyspepsia is functional dyspepsia or nonulcer dyspepsia.

57 . The method of claim 55 , wherein the dyspepsia is functional dyspepsia.

58 . A method for treating a patient suffering from a gastrointestinal disorder selected from the group consisting of gastroparesis and dyspepsia; the method comprising orally administering to the patient a composition comprising a polypeptide consisting of the amino acid sequence Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu (SEQ ID NO: 73) or Asn Asp Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu (SEQ ID NO: 44), wherein the polypeptide activates the guanylate cyclase C receptor, thereby treating the disorder.

59 . The method of claim 58 , wherein the gastrointestinal disorder is gastroparesis.

60 . The method of claim 58 , wherein the gastrointestinal disorder is dyspepsia.

61 . The method of claim 60 , wherein the dyspepsia is functional dyspepsia or nonulcer dyspepsia.

62 . The method of claim 60 , wherein the dyspepsia is functional dyspepsia.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 5, 2012
From: CURRIE, MARK G.; MAHAJAM-MIKLOS, SHALINA; SUN, LI JING
To: MICROBIA, INC.
Reel/Frame 028321/0793 →
CHANGE OF NAME Recorded Jun 5, 2012
From: MICROBIA, INC.
To: IRONWOOD PHARMACEUTICALS, INC.
Reel/Frame 028324/0785 →